CT.gov Oncology Hiddenness
2026-03-29 | full-registry ct.gov audit | plots, figures, and e156 bundle
Series
Oncology Dashboard

Oncology hiddenness becomes clearer when sponsor class, phase structure, and stock are separated

The oncology dashboard isolates family-specific sponsor mix, phase mix, and leading sponsors rather than folding them into an all-registry average.

Sponsor classes
Phases
Top sponsors
Family-specific stock

Dashboard

The oncology story is about both scale and structure: very large stock, weak early-phase visibility, and heavy concentration in major sponsors.

How to read the dashboard
Eligible older
42,344
Oncology studies
No-results rate
67.0%
2-year no-results
Largest phase bucket
14,147
PHASE2
Top sponsor stock
909
National Cancer Institute (NCI)
Sponsor-class rates
ONCOLOGY SPONSOR CLASSES2-year no-results rate by sponsor class within oncology studiesOTHER_GOV96.1%OTHER72.6%NETWORK66.9%INDUSTRY56.5%NIH48.9%FED44.0%
OTHER_GOV remains near the top where present, but the broader oncology burden is still shaped by the much larger OTHER and INDUSTRY blocks.
This is a family-specific rate view, so it should be read alongside the top-sponsor stock chart rather than as a standalone leaderboard.
Phase pattern
ONCOLOGY PHASES2-year no-results rate by phase inside the oncology familyEARLY_PHASE187.9%PHASE185.1%nan82.4%PHASE2 | PHASE375.7%PHASE469.1%PHASE356.5%PHASE1 | PHASE251.2%PHASE250.8%
EARLY_PHASE1 is the quietest major phase inside the oncology family on the no-results metric.
Phase structure matters because the family-level average can hide very different early-phase and late-phase behavior.
Largest sponsor stocks
ONCOLOGY TOP SPONSORSLead sponsors with the largest missing-results stock inside oncology studiesNational Cancer Institute (NCI)909M.D. Anderson Cancer Center589Memorial Sloan Kettering Cancer Center391Novartis Pharmaceuticals309University Health Network, Toronto239Dana-Farber Cancer Institute223Mayo Clinic217Alliance for Clinical Trials in Oncology206European Organisation for Research and Treatment of Cancer - EORTC205Sanofi195
National Cancer Institute (NCI) carries the largest named missing-results stock in this family at 909 studies.
The top-sponsor chart makes the family-specific backlog concrete instead of leaving it as a single family-wide percentage.
Read Across Projects

Across The Series

Each project isolates a different dimension of registry opacity, but the point is the contrast between them, not a single leaderboard.

Industry
CT.gov Industry Disclosure Gap

Industry-focused missing-results stock, sponsor backlogs, and structural sparsity inside CT.gov.

Sponsor Classes
CT.gov Sponsor-Class Hiddenness

Sponsor-class comparisons on rate, stock, and structural hiddenness rather than one flattened ranking.

Phases
CT.gov Phase Reporting Gap

Phase-by-phase disclosure gaps showing how silence changes along the development pathway.

Structural
CT.gov Structural Missingness

Field-level missingness across publication links, IPD statements, descriptions, and locations.

Visibility
CT.gov Evidence Visibility Gap

Results-plus-publication visibility states showing how many older trials are fully visible, partly visible, or ghosted.

Cohorts
CT.gov Completion Cohort Debt

Completion-era reporting debt showing how older eligible cohorts drift on no-results and ghost-protocol rates.

Conditions
CT.gov Condition Hiddenness Map

Keyword-classified therapeutic-area hiddenness mapping across common condition families.

Concentration
CT.gov Sponsor Backlog Concentration

Concentration and inequality analysis showing how much unresolved stock sits inside a thin sponsor slice.

Rule Eras
CT.gov Rule-Era Reporting Gap

Policy-era comparisons across pre-FDAAA, FDAAA, and later CT.gov completion cohorts.

PubMed Audit
CT.gov Publication Undercount Audit

Sample-based external PubMed NCT audit testing how often CT.gov no-link records hide an external paper trail.

Cardiovascular
CT.gov Cardiovascular Hiddenness

Cardiovascular CT.gov hiddenness showing how heart and vascular studies remain quiet across major phases and sponsors.

Metabolic
CT.gov Metabolic Hiddenness

Metabolic CT.gov hiddenness across obesity, diabetes, and related trial portfolios with large late-phase and NA stock.